Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Daniel Prieto-Alhambra"'
Autor:
M Sanni Ali, Daniel Dedman, Leena Elhussein, Nigel K Arden, Danielle E Robinson, Andrew Judge, Yoav Ben-Shlomo, Bo Abrahamsen, Muhammad Javaid, Daniel Prieto-Alhambra, Victoria Y Strauss, Antonella Delmestri, Cyrus Cooper, Fergus Caskey
Publikováno v:
Health Technology Assessment, Vol 25, Iss 17 (2021)
Robinson, D E, Sanni Ali, M, Strauss, V, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F J, Cooper, C, Dedman, D J, Delmestri, A, Judge, A, Javaid, M K & Prieto-Alhambra, D 2021, ' Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease : a propensity-score matched cohort study ', Health Technology Assessment, vol. 25, no. 17, pp. i-xxviii, 1-105 . https://doi.org/10.3310/hta25170
Health Technol Assess
Robinson, D E, Ali, M S, Strauss, V Y, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Javaid, M K & Prieto-Alhambra, D 2021, ' Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease : a propensity score-matched cohort study ', Health Technology Assessment, vol. 25, no. 17 . https://doi.org/10.3310/hta25170
Robinson, D E, Sanni Ali, M, Strauss, V, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F J, Cooper, C, Dedman, D J, Delmestri, A, Judge, A, Javaid, M K & Prieto-Alhambra, D 2021, ' Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease : a propensity-score matched cohort study ', Health Technology Assessment, vol. 25, no. 17, pp. i-xxviii, 1-105 . https://doi.org/10.3310/hta25170
Health Technol Assess
Robinson, D E, Ali, M S, Strauss, V Y, Elhussein, L, Abrahamsen, B, Arden, N K, Ben-Shlomo, Y, Caskey, F, Cooper, C, Dedman, D, Delmestri, A, Judge, A, Javaid, M K & Prieto-Alhambra, D 2021, ' Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease : a propensity score-matched cohort study ', Health Technology Assessment, vol. 25, no. 17 . https://doi.org/10.3310/hta25170
Bisphosphonates are contraindicated in patients with stage 4+ chronic kidney disease. However, they are widely used to prevent fragility fractures in stage 3 chronic kidney disease, despite a lack of good-quality data on their effects.The aims of eac